Article

FDA denies CLIA waiver

The FDA has notified TearLab Corp. that the agency cannot approve the company?s Clinical Laboratory Improvement Amendments (CLIA) waiver categorization application for its osmolarity system (TearLab Osmolarity System) based on the data submitted, according to the company

San Diego-The FDA has notified TearLab Corp. that the agency cannot approve the company’s Clinical Laboratory Improvement Amendments (CLIA) waiver categorization application for its osmolarity system (TearLab Osmolarity System) based on the data submitted, according to the company.

“While we are evaluating the FDA’s letter to determine a clear path toward CLIA waiver, we believe that the success of our recently announced Laboratory Director for Moderate Complexity Program gives us the flexibility and time to consider all of our regulatory options,” said Elias Vamvakas, TearLab’s chief executive officer. “With FDA 510(k) approval, Medicare reimbursement, and more than 120 doctors having already completed all of the program steps-20 of which having received their lab director’s certifications to date-we are fully engaged in our U.S. commercialization program.”

The osmolarity system uses a novel lab-on-a-chip approach that requires less than 50 nl of tear fluid to measure tear osmolarity. It can produce a sample-to-answer result in less than 30 seconds, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.